Patients with chronic hepatitis type C and interferon-alpha-induced hyperthyroidism in two-years clinical follow-up

Neuroendocrinology Letters

Volumn 34, Issue 2, 2013, Pages 154-161

  Czarnywojtek, Agata ^a   Zgorzalewicz Stachowiak, Małgorzata ^a   Waško, Ryszard ^a   Czepczynski, Rafał ^a   Szczepanek Parulska, Ewelina ^a   Waligorska Stachura, Joanna ^a   Kurdybacha, Peter ^a   Bereszyńska, Iwona ^a   Florek, Ewa ^a   Stangierski, Adam ^a   Zdanowska, Joanna ^a   Nikisch, Elzbieta ^a   Sowiński, Jerzy ^a   Ruchała, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

C viral hepatitis; Graves' disease; Hashitoxicosis; Interferon induced hyperthyroidism; Radioiodine therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 131; PROPYLTHIOURACIL; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; THIAMAZOLE; THYROID ANTIBODY; THYROID HORMONE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; GRAVES DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; THYROID FUNCTION;

EID: 84878240171     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, et al (2008). Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 18: 333-346. (Pubitemid 351415802)
2. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. (1996). Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 81: 2930-2933. (Pubitemid 26323888)
3. Binaghi M, Lévy C, Douvin C, Guittard M, Soubrane,G, Coscas G. (2002). Severe thyroid ophthalmopathy related to interferon alpha therapy J Fr Ophtalmol. 25: 412-415. (Pubitemid 34493654)
4. Bogazzi F, Bartalena L, Brogioni S, Mazzeo S, Vitti P, Burelli A, et al (1997). Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis.Thyroid. 7: 541-545. (Pubitemid 27371790)
5. Bohbot NL, Young J, Orgiazzi J, Buffet C, François M, Bernard-Chabert B, et al. (2006). Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. Eur J Endocrinol. 154:367-372.
6. Braga-Basaria M, Basaría S. (2003). Interferon-α-induced transient severe hypothyroidism in a patient with Graves' disease. J Endocrinol Invest. 26: 261-264 (Pubitemid 36681747)
7. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. (2004). Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 89: 3656-3661. (Pubitemid 39071450)
8. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, et al. (1995). Longitudinal study of antibodies against thyroid in patients undergoing interferon therapy for HCV chronic hepatitis. Horm Res. 44: 110-114.
9. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, et al. (2001). Long-Term Outcome of Interferon-α-Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. J Clin Endocrinol Metab. 86: 1925-1929.
10. Csaki AC, Blum M. (2000). Thyrotoxicosis after interferon- therapy. Thyroid. 10:101.
11. Czarnywojtek A, Czepczynski R, Ruchala M, Wasko R, Zgorzalewicz- Stachowiak M, Szczepanek E, et al (2009). Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). Neuro Endocrinol Lett. 30: 209-214.
12. Czarnywojtek A, Waligórska-Stachura J, Szczepanek-Parulska E, Zgorzalewicz-Stachowiak M, Bereszyńska I, et al (2012). A rare case of Interferon-alpha-Induced Hyperthyroidism in patients with a chronic hepatitis C with granulocytopenia and transaminasemia treated successfully with radioiodine. Neuro Endocrinol Lett. 33: 101-105.
13. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al (1997). Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon therapy. Hepatology. 26: 206-210. (Pubitemid 27280326)
14. Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C (2009). Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol. 15: 328-333.
15. Hsieh MC, Yu ML, Chuang,WL, Shin SJ, Dai CY, Chen SC, et al (2000). Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol. 142: 431-437.
16. Knudsen N, Bols B, Bulow I, Jorgensen T, Perrild H et al (1999). Validation of ultrasonography of the thyroid gland for epidemiological purposes. Thyroid. 9: 1069-1074.
17. Koh LK, Greenspan FS, Yeo PP (1997). Interferon-alpha induced thyroid dysfunction: three clinical presentations and review of the literature. Thyroid. 7: 891-896. (Pubitemid 28041664)
18. Mandac J, C, Chaudbry S, Sherman KE, Tomer Y (2006). The clincaland physiological spectrum of interferon-α induced thyroiditis: toward a new classification. Hepatology. 43: 661-672.
19. Martino E, Aghjini-F, Mariotti S, Bartalena L, Braverman L, Pinchera A (1987). Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 26: 158-171.
20. Martino E, Bartalena L, Bogazzi F, Braverman LE (2001). Amiodarone and the thyroid. Endocr Rev. 22: 240-254.
21. Moncoucy X, Leymarie F, Delemer B, Lévy S, Bernard-Chabert B, Bouché O, et al (2005). Risk factors and long-term evolution of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol. 29: 339-345. (Pubitemid 40646477)
22. Obołończyk L, Obołończyk L, Siekierska-Hellmann M, Sworczak K, et al (2007). Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction. Postepy Hig Med Dosw. 26: 309-21.
23. Patient's Rights and Patient's Rights Representative Act from 6 November 2008. Journal of Laws of the Republic of Poland 2009; 52:417.
24. Ruchała M, Szczepanek E (2011). The role of sonoelastography in acute, subacute and chronic thyroiditis: a novel application of the method. Endokrynol Pol. 62: 8-24.
25. Ruchala M, Szczepanek-Parulska E, Zybek A, Moczko J, Czarnywojtek A, Kaminski G, et al (2012). The role of sonoelastography in acute, subacute and chronic thyroiditis: a novel application of the method. Eur J Endocrinol. 3: 425-32.
26. Schiemann U, Walli R, Schmidt F, Bogner J, Gross M. (2002). Thyroid hypoechogenicity in patients with chronic hepatitis receiving interferon- therapy: evaluation by standardized grey scale ultrasonography. Eur J Med Res. 7: 271-277.
27. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ (2007). Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol. 13: 1292-1294. (Pubitemid 46592980)
28. Tomer Y. (2010). Hepatitis C and interferon induced thyroiditis. J Autoimmun. 34: 322-326.
29. Tran HA. (2010).The swinging thyroid in hepatitis C infection and interferon therapy. QJM. 103: 187-91.
30. Tran HA, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, et al (1993). High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 18: 253-257 (Pubitemid 23225092)
31. Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G (2009). Thyroid dysfunction in patients with chronic hepatitis C: Virus- or therapy-related? J Gastroenterol Hepatol. 24: 1024-1029.
32. Wong V, Xi-Li Fu A, George J, Wah Cheung N (2002).Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf). 56: 793-798. (Pubitemid 34785912)